GLPG — Galapagos N.V.

Summary of Galapagos Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Operating Profit: Galapagos reported an operating profit of EUR 295.1 million for 2025, a significant turnaround from an operating loss of EUR 188.3 million in 2024. This profit was largely due to the recognition of EUR 1,069 million in revenue from the deferred income balance related to the Gilead agreement.
• Operating Expenses: Total operating expenses were EUR 399.8 million, heavily impacted by the wind-down of cell therapy activities, which incurred costs of EUR 275 million.
• Cash Position: At year-end 2025, the company had approximately EUR 3 billion in cash and cash equivalents, down from EUR 3.3 billion in 2024. The cash mix shifted to 72% in U.S. dollars, reflecting a strategic move to align with anticipated business development activities.
• Future Cash Flow: Galapagos expects to be cash flow neutral to positive by the end of 2026, with projected cash reserves of EUR 2.775 billion to EUR 2.850 billion.

2. Strategic Updates and Business Highlights

• New Strategic Direction: The company is transitioning away from cell therapy and focusing on business development opportunities in the immunology and oncology sectors, leveraging a newly assembled management team with significant industry experience.
• Collaboration with Gilead: The partnership with Gilead is viewed as a strategic advantage, providing access to global development expertise and potential financial support for future deals.
• TYK2 Program Update: The Phase II results for GLPG3667 in dermatomyositis and systemic lupus erythematosus were positive, with plans to explore strategic partnerships for further development.

3. Forward Guidance and Outlook

• Cell Therapy Wind-Down: The wind-down of cell therapy activities is expected to be substantially completed by Q3 2026, with a one-time restructuring cash impact projected between EUR 125 million and EUR 175 million for 2026.
• Cost Management: The company anticipates ongoing costs related to the TYK2 program and aims to manage expenses carefully while pursuing business development opportunities.

4. Bad News, Challenges, or Points of Concern

• High Operating Expenses: The significant costs associated with the cell therapy wind-down and restructuring could impact short-term financial performance.
• Dependency on Business Development: The company’s future success hinges on successfully executing business development transactions before the expiration of the Gilead agreement in approximately three years.
• Market Competition: The focus on late-stage clinical assets in a competitive biotech landscape poses risks, as the company must identify and secure promising opportunities.

5. Notable Q&A Insights

• Business Development Focus: Management reiterated a disciplined approach to business development, emphasizing the importance of identifying derisked late-stage assets without setting a strict deadline for transactions.
• Capital Allocation Strategy: The company aims to balance its cash reserves for operational needs while leveraging its partnership with Gilead to expand its deal-making capabilities.
• Future of GLPG3667: The management maintains a high bar for internal investment in the TYK2 program, indicating a preference for potential partnerships to accelerate development rather than solely relying on internal resources.

Overall, Galapagos is navigating a significant transformation with a focus on strategic business development while managing the financial implications of its past cell therapy endeavors. The company expresses optimism about its future prospects, driven by a strong cash position and strategic partnerships.